Drugs / Fulvestrant
Fulvestrant
also known as
Faslodex · ICI 182,780 · Fulvestrant (Faslodex) · Fulvestrant mylan · KSHN001034 · NSC #719276 · NSC-759879 · ZD-9238
Small molecule targets AR, ESR1 via inhibition
Regulatory milestones approvals, filings & regulatory actions · 15 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Label expansion | US (FDA) | FULVESTRANT | — | 2021-05-12 | fda.gov ↗ |
| Label expansions (12) | US (FDA) | FASLODEX | — | 2003-12-24 – 2020-07-28 | fda.gov ↗ |
| Approved | EU (EMA) | Faslodex | — | 2004-03-09 | europa.eu ↗ |
| Approved | US (FDA) | FASLODEX | — | 2002-04-25 | fda.gov ↗ |
Trials 298 · started per year
today
US approved 2002
EU approved 2004
1
1
2
1
1
2
13
5
8
7
8
4
4
4
4
2
13
10
18
23
18
15
15
18
28
22
22
18
11
19971998199920002001200220032004200520062007200820092010201120122013201420152016201720182019202020212022202320242025202620272028
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT05238831 | Jan 2023 → May 2026 | female breast carcinoma, ovarian carcinoma, pancreatic ductal adenocarcinoma, pancreatic large cell neuroendocrine carcinoma +2 | OHSU Knight Cancer Institute | Withdrawn | No outcome recorded |
| Phase 150 trials | ||||||
| Phase 1 | NCT07604272 | Jul 2026 → Jun 2028 expected | hernia, double inguinal | Northwestern University | Recruiting | No outcome recorded |
| Phase 1 | NCT07604571 | May 2026 → Jun 2032 expected | hormone receptor-positive breast cancer | Novartis Pharmaceuticals | Recruiting | No outcome recorded |
| Phase 1 | NCT07540572 | Mar 2026 → Mar 2030 expected | castration-resistant prostate carcinoma, colorectal carcinoma, estrogen-receptor positive breast cancer, non-small cell lung carcinoma | IDEAYA Biosciences | Recruiting | No outcome recorded |
| Phase 1 | NCT07226349 | Dec 2025 → Nov 2028 expected | neoplasm | BeOne Medicines | Recruiting | No outcome recorded |
| Phase 1 | NCT07163481 | Oct 2025 → Dec 2026 expected | female breast carcinoma | Hunan Cancer Hospital | Not yet recruiting | No outcome recorded |
| Phase 1 | NCT06995482 | Aug 2025 → May 2026 overdue | — | Kashiv BioSciences, LLC | Recruiting | No outcome recorded |
| Phase 1 | NCT07038369 | Jul 2025 → Aug 2028 expected | cervical carcinoma, endometrial carcinoma, estrogen-receptor positive breast cancer, fallopian tube cancer +3 | Atavistik Bio, Inc | Active not recruiting | No outcome recorded |
| Phase 1 | NCT06784193 | Dec 2024 → May 2027 expected | castration-resistant prostate carcinoma, estrogen-receptor positive breast cancer, non-small cell lung carcinoma, progesterone-receptor positive breast cancer | Olema Pharmaceuticals, Inc. | Recruiting | No outcome recorded |
| Phase 1 | NCT06663072 | Dec 2024 → Nov 2026 expected | pancreatic neuroendocrine tumor | University of Chicago | Recruiting | No outcome recorded |
| Phase 1 | NCT06515470 | Jul 2024 → Sep 2027 expected | breast cancer | Biotheryx, Inc. | Recruiting | No outcome recorded |
| Phase 1 | NCT06253195 | Apr 2024 → Apr 2026 | hormone receptor-positive breast cancer, metastatic neoplasm | BeOne Medicines | Completed | No outcome recorded |
| Phase 1 | NCT06257264 | Mar 2024 → Aug 2026 overdue | endometrial cancer, gastric cancer, gastroesophageal cancer, hormone receptor-positive breast cancer +5 | BeiGene | Active not recruiting | No outcome recorded |
| Phase 1 | NCT05905341 | Jan 2024 → Apr 2026 | breast cancer, endometrial cancer, liposarcoma, non-small cell lung carcinoma +1 | Pfizer | Withdrawn | No outcome recorded |
| Phase 1 | NCT06120283 | Dec 2023 → Nov 2028 expected | hormone receptor-positive breast cancer, non-small cell lung carcinoma | BeOne Medicines | Recruiting | No outcome recorded |
| Phase 1 | NCT05759949 | Mar 2023 → Mar 2025 | PIK3CA-related overgrowth spectrum, hormone receptor-positive breast cancer | Relay Therapeutics, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT06074757 | Mar → Sep 2023 | breast cancer | Kashiv BioSciences, LLC | Completed | No outcome recorded |
| Phase 1 | NCT05238922 | Jul 2022 → Jul 2027 expected | cancer | Incyte Corporation | Recruiting | No outcome recorded |
| Phase 1 | NCT05252416 | Apr 2022 → Jul 2025 | carcinosarcoma, endometrial cancer, esophageal adenocarcinoma, gastric cancer +2 | Blueprint Medicines Corporation | Terminated | No outcome recorded |
| Phase 1 | NCT05504213 | Jan 2022 → Jul 2023 | breast cancer | Jiangsu Hansoh Pharmaceutical Co., Ltd. | Unknown | No outcome recorded |
| Phase 1 | NCT04316169 | Oct 2021 → Jan 2027 | female breast carcinoma | Medical College of Wisconsin | Withdrawn | No outcome recorded |
| Phase 1 | NCT04556773 | Dec 2020 → Aug 2023 overdue | breast cancer | AstraZeneca | Active not recruiting | No outcome recorded |
| Phase 1 | NCT04483505 | Nov 2020 → Apr 2023 | hormone receptor-positive breast cancer | CRIS Cancer Foundation | Completed | No outcome recorded |
| Phase 1 | NCT03685331 | Oct 2020 → Aug 2025 | BRCA1-related cancer predisposition, BRCA2-related cancer predisposition, breast cancer | Abramson Cancer Center at Penn Medicine | Completed | No outcome recorded |
| Phase 1 | NCT03554044 | Feb 2020 → Dec 2023 | Her2-receptor negative breast cancer, estrogen-receptor positive breast cancer, female breast carcinoma, invasive breast carcinoma | University of California, San Francisco | Completed | No outcome recorded |
| Phase 1 | NCT02964507 | Sep 2019 → Sep 2020 | neoplasm | GlaxoSmithKline | Terminated | No outcome recorded |
| Phase 1 | NCT06047184 | Jul 2019 → Oct 2023 | female breast carcinoma | BeBetter Med Inc | Unknown | No outcome recorded |
| Phase 1 | NCT03959891 | May 2019 → Dec 2022 overdue | breast cancer | Massachusetts General Hospital | Active not recruiting | No outcome recorded |
| Phase 1 | NCT03854903 | Apr 2019 → Nov 2023 | hormone receptor-positive breast cancer | Georgetown University | Completed | No outcome recorded |
| Phase 1 | NCT03767335 | Nov 2018 → Feb 2024 | breast cancer | Menarini Group | Completed | No outcome recorded |
| Phase 1 | NCT03294694 | Nov 2017 → Oct 2020 | hormone receptor-positive breast cancer, malignant epithelial tumor of ovary | Dana-Farber Cancer Institute | Terminated | No outcome recorded |
| Phase 1 | NCT03308201 | Oct 2017 → Jun 2022 | breast cancer | Tianjin Hemay Pharmaceutical Co., Ltd | Completed | No outcome recorded |
| Phase 1 | NCT03238196 | Aug 2017 → Apr 2021 | breast cancer | Vanderbilt-Ingram Cancer Center | Completed | No outcome recorded |
| Phase 1 | NCT03099174 | May 2017 → May 2023 | breast neoplasm | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 1 | NCT03006172 | Dec 2016 → Dec 2026 expected | breast cancer | Genentech, Inc. | Active not recruiting | No outcome recorded |
| Phase 1 | NCT02936206 | Oct 2016 → May 2020 | breast cancer | Icahn School of Medicine at Mount Sinai | Terminated | No outcome recorded |
| Phase 1 | NCT02761694 | Jun 2016 → Mar 2021 | cancer | ArQule, Inc. | Terminated | No outcome recorded |
| Phase 1 | NCT02684032 | Jun 2016 → Jan 2022 | breast cancer | Celcuity Inc | Completed | No outcome recorded |
| Phase 1 | NCT02640755 | Jan → Dec 2016 | cancer | AstraZeneca | Completed | No outcome recorded |
| Phase 1 | NCT02626507 | Jan 2016 → Feb 2022 | breast cancer | Hoffman Oncology | Unknown | No outcome recorded |
| Phase 1 | NCT02384746 | Jun 2015 → Apr 2018 | breast cancer | Dartmouth-Hitchcock Medical Center | Terminated | No outcome recorded |
| Phase 1 | NCT02333370 | Feb 2015 → Sep 2022 | hormone receptor-positive breast cancer | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 1 | NCT02088684 | May 2014 → Apr 2018 | breast cancer | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 1 | NCT02057133 | Mar 2014 → Mar 2021 overdue | breast neoplasm | Eli Lilly and Company | Active not recruiting | No outcome recorded |
| Phase 1 | NCT02026973 | Mar 2014 → Nov 2015 | — | Mayo Clinic | Completed | No outcome recorded |
| Phase 1 | NCT01344031 | Apr → Jul 2011 | estrogen-receptor positive breast cancer, invasive breast carcinoma | National Cancer Institute (NCI) | Completed | No outcome recorded |
| Phase 1 | NCT01219699 | Oct 2010 → Feb 2015 | estrogen-receptor positive breast cancer | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 1 | NCT01394016 | Dec 2009 → May 2014 | — | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 1 | NCT01004419 | Nov 2009 → Nov 2010 | non-small cell lung carcinoma | University of Wisconsin, Madison | Withdrawn | No outcome recorded |
| Phase 1 | NCT01186796 | Jun 2009 → Jun 2013 | — | Mayo Clinic | Completed | No outcome recorded |
| Phase 1 | NCT00328120 | Apr 2004 → Apr 2006 | female breast carcinoma | AstraZeneca | Completed | No outcome recorded |
| Phase 1/238 trials | ||||||
| Phase 1/2 | NCT07570966 | Jun 2026 → Aug 2031 | castration-resistant prostate carcinoma, hormone receptor-positive breast cancer | Novartis Pharmaceuticals | Withdrawn | No outcome recorded |
| Phase 1/2 | NCT07389733 | Mar 2026 → Dec 2028 expected | breast cancer | Shandong Suncadia Medicine Co., Ltd. | Recruiting | No outcome recorded |
| Phase 1/2 | NCT07235176 | Jan 2026 → Nov 2028 expected | Her2-receptor negative breast cancer | Qilu Pharmaceutical Co., Ltd. | Recruiting | No outcome recorded |
| Phase 1/2 | NCT07288359 | Dec 2025 → May 2031 expected | castration-resistant prostate carcinoma, hormone receptor-positive breast cancer | Novartis Pharmaceuticals | Recruiting | No outcome recorded |
| Phase 1/2 | NCT06998407 | Aug 2025 → Aug 2028 expected | hormone receptor-positive breast cancer | Avenzo Therapeutics, Inc. | Recruiting | No outcome recorded |
| Phase 1/2 | NCT06851442 | May → Nov 2025 | breast cancer | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Terminated | No outcome recorded |
| Phase 1/2 | NCT06726148 | Apr 2025 → Sep 2028 expected | hormone receptor-positive breast cancer, small cell lung carcinoma | Novartis Pharmaceuticals | Recruiting | No outcome recorded |
| Phase 1/2 | NCT06788197 | Mar 2025 → Mar 2028 expected | breast cancer | Henan Cancer Hospital | Not yet recruiting | No outcome recorded |
| Phase 1/2 | NCT06555068 | Aug 2024 → Dec 2027 expected | breast cancer | Jiangsu HengRui Medicine Co., Ltd. | Recruiting | No outcome recorded |
| Phase 1/2 | NCT05986071 | May 2024 → Apr 2027 expected | breast cancer | Institut Paoli-Calmettes | Not yet recruiting | No outcome recorded |
| Phase 1/2 | NCT06208410 | Jan 2024 → Feb 2027 expected | neoplasm | Risen (Suzhou) Pharma Tech Co., Ltd. | Recruiting | No outcome recorded |
| Phase 1/2 | NCT06110793 | Dec 2023 → Nov 2027 expected | breast cancer | Memorial Sloan Kettering Cancer Center | Recruiting | No outcome recorded |
| Phase 1/2 | NCT05867251 | Aug 2023 → Jan 2028 expected | endometrial cancer, fallopian tube cancer, hormone receptor-positive breast cancer, malignant epithelial tumor of ovary +2 | Avenzo Therapeutics, Inc. | Recruiting | No outcome recorded |
| Phase 1/2 | NCT06202261 | Apr 2023 → Dec 2026 expected | breast carcinoma | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Recruiting | No outcome recorded |
| Phase 1/2 | NCT05792410 | Apr 2023 → Feb 2024 | Her2-receptor negative breast cancer | Jiangsu HengRui Medicine Co., Ltd. | Unknown | No outcome recorded |
| Phase 1/2 | NCT05608252 | Feb 2023 → Dec 2027 expected | hormone receptor-positive breast cancer | Adrienne G. Waks | Recruiting | No outcome recorded |
| Phase 1/2 | NCT05574881 | Sep 2022 → Jan 2025 | breast cancer | Fudan University | Unknown | No outcome recorded |
| Phase 1/2 | NCT05191004 | Sep 2022 → Jun 2025 | breast carcinoma | Nuvation Bio Inc. | Withdrawn | No outcome recorded |
| Phase 1/2 | NCT05251714 | May 2022 → Aug 2026 overdue | breast cancer | Treadwell Therapeutics, Inc | Active not recruiting | No outcome recorded |
| Phase 1/2 | NCT05319873 | Apr 2022 → Apr 2027 expected | HER2 positive breast carcinoma, invasive breast carcinoma | Jonsson Comprehensive Cancer Center | Active not recruiting | No outcome recorded |
| Phase 1/2 | NCT05262400 | Mar 2022 → Aug 2026 overdue | breast cancer | Pfizer | Active not recruiting | No outcome recorded |
| Phase 1/2 | NCT05176080 | Dec 2021 → Jul 2024 | breast cancer | Henan Cancer Hospital | Terminated | No outcome recorded |
| Phase 1/2 | NCT04282031 | Jun 2020 → Dec 2024 overdue | hormone receptor-positive breast cancer | Beta Pharma (Suzhou) Co., Ltd. | Recruiting | No outcome recorded |
| Phase 1/2 | NCT04092673 | Oct 2019 → Dec 2024 | cancer | Effector Therapeutics | Unknown | No outcome recorded |
| Phase 1/2 | NCT03772353 | May 2019 → Jun 2023 | breast cancer | Fudan University | Unknown | No outcome recorded |
| Phase 1/2 | NCT03803761 | Feb 2019 → Feb 2022 | female breast carcinoma, invasive breast carcinoma, metastatic malignant neoplasm in the brain | National Cancer Institute (NCI) | Withdrawn | No outcome recorded |
| Phase 1/2 | NCT03169777 | Aug 2018 → Jan 2019 | colorectal cancer | ImmunityBio, Inc. | Withdrawn | No outcome recorded |
| Phase 1/2 | NCT03424005 | Mar 2018 → Sep 2030 expected | breast cancer | Hoffmann-La Roche | Recruiting | No outcome recorded |
| Phase 1/2 | NCT03481998 | Mar 2018 → Jul 2022 | breast cancer | Jiangsu HengRui Medicine Co., Ltd. | Completed | No outcome recorded |
| Phase 1/2 | NCT03519178 | Mar 2018 → Apr 2023 | breast cancer | Pfizer | Terminated | No outcome recorded |
| Phase 1/2 | NCT03169738 | Feb 2018 → Jan 2019 | non-small cell lung carcinoma | ImmunityBio, Inc. | Withdrawn | No outcome recorded |
| Phase 1/2 | NCT03280563 | Dec 2017 → Sep 2024 | breast neoplasm | Hoffmann-La Roche | Completed | No outcome recorded |
| Phase 1/2 | NCT03197584 | Dec 2017 → Feb 2019 | ovarian carcinoma | ImmunityBio, Inc. | Withdrawn | No outcome recorded |
| Phase 1/2 | NCT03197571 | Dec 2017 → Jan 2019 | urothelial carcinoma | ImmunityBio, Inc. | Withdrawn | No outcome recorded |
| Phase 1/2 | NCT03169764 | Dec 2017 → Jan 2019 | head and neck squamous cell carcinoma | ImmunityBio, Inc. | Withdrawn | No outcome recorded |
| Phase 1/2 | NCT03344536 | Nov 2017 → Aug 2021 | breast cancer | Memorial Sloan Kettering Cancer Center | Completed | No outcome recorded |
| Phase 1/2 | NCT02657343 | Mar 2016 → Aug 2020 | breast cancer | Dana-Farber Cancer Institute | Completed | No outcome recorded |
| Phase 1/2 | NCT02345772 | Jul 2014 → Nov 2015 | HER2 positive breast carcinoma, estrogen-receptor positive breast cancer | Western Regional Medical Center | Terminated | No outcome recorded |
| Phase 2157 trials | ||||||
| Phase 2 | NCT07340619 | May 2026 → Nov 2028 expected | metastatic melanoma | UNICANCER | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07227233 | Mar 2026 → Dec 2027 expected | breast cancer | University of California, San Diego | Recruiting | No outcome recorded |
| Phase 2 | NCT07498478 | Mar 2026 → Jun 2027 expected | breast cancer | TransThera Sciences (Nanjing), Inc. | Recruiting | No outcome recorded |
| Phase 2 | NCT07235618 | Jan 2026 → Jan 2028 expected | breast cancer | Sun Yat-sen University | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07333937 | Dec 2025 → Nov 2027 expected | breast cancer | Xijing Hospital | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07330544 | Nov 2025 → Nov 2027 expected | breast cancer | Zhejiang Cancer Hospital | Recruiting | No outcome recorded |
| Phase 2 | NCT07179939 | Sep 2025 → Dec 2030 expected | HER2 positive breast carcinoma | Fudan University | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07037199 | Aug 2025 → Jun 2028 expected | breast cancer | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | Recruiting | No outcome recorded |
| Phase 2 | NCT06979596 | Aug 2025 → Nov 2027 expected | cancer | Merck Sharp & Dohme LLC | Recruiting | No outcome recorded |
| Phase 2 | NCT06494150 | Dec 2024 → Aug 2027 expected | ovarian serous adenocarcinoma | University of Oklahoma | Active not recruiting | No outcome recorded |
| Show all 157 trials opens the full record — a long page | ||||||
| Phase 2/34 trials | ||||||
| Phase 2/3 | NCT06506955 | Oct 2024 → Apr 2027 expected | metastatic neoplasm | Taiho Oncology, Inc. | Enrolling by invitation | No outcome recorded |
| Phase 2/3 | NCT04753177 | Jan 2021 → Jan 2023 | — | Saint Petersburg State Budgetary Healthcare Institution, City Clinical Oncology Dispensary | Unknown | No outcome recorded |
| Phase 2/3 | NCT02692755 | Sep 2016 → Dec 2019 | hormone receptor-positive breast cancer | Georgetown University | Completed | No outcome recorded |
| Phase 2/3 | NCT02116803 | May 2014 → Nov 2016 | cancer | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 337 trials | ||||||
| Phase 3 | NCT07683754 | Sep 2026 → Jul 2030 expected | HER2 positive breast carcinoma, female breast carcinoma, hormone receptor-positive breast cancer | Daiichi Sankyo | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT07062965 | Aug 2025 → Jul 2027 expected | breast cancer | Pfizer | Recruiting | No outcome recorded |
| Phase 3 | NCT06757634 | Jul 2025 → Mar 2029 expected | breast cancer | Celcuity Inc | Recruiting | No outcome recorded |
| Phase 3 | NCT06764186 | Jan 2025 → Dec 2027 expected | breast cancer | AstraZeneca | Active not recruiting | No outcome recorded |
| Phase 3 | NCT06635447 | Sep 2024 → Oct 2026 expected | breast cancer | AstraZeneca | Active not recruiting | No outcome recorded |
| Phase 3 | NCT05646862 | Jun 2023 → Nov 2026 expected | breast cancer | Hoffmann-La Roche | Active not recruiting | No outcome recorded |
| Phase 3 | NCT05501886 | Dec 2022 → Jun 2026 overdue | breast cancer | Celcuity Inc | Active not recruiting | No outcome recorded |
| Phase 3 | NCT04851613 | Feb 2022 → Oct 2026 expected | breast cancer | Laekna Limited | Active not recruiting | No outcome recorded |
| Phase 3 | NCT04975308 | Oct 2021 → Jun 2024 overdue | breast cancer, metastatic malignant neoplasm | Eli Lilly and Company | Active not recruiting | No outcome recorded |
| Phase 3 | NCT05063786 | Sep 2021 → Jun 2026 overdue | breast cancer | Spanish Breast Cancer Research Group | Active not recruiting | No outcome recorded |
| Phase 3 | NCT04862663 | May 2021 → Nov 2027 expected | Her2-receptor negative breast cancer | AstraZeneca | Recruiting | No outcome recorded |
| Phase 3 | NCT04646759 | Oct 2020 → Dec 2028 expected | breast cancer | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | Recruiting | No outcome recorded |
| Phase 3 | NCT04337658 | Jul 2020 → Apr 2024 | HER2 positive breast carcinoma | Second Affiliated Hospital, School of Medicine, Zhejiang University | Unknown | No outcome recorded |
| Phase 3 | NCT04158362 | Jun 2020 → Apr 2025 overdue | metastatic malignant neoplasm | UNICANCER | Active not recruiting | No outcome recorded |
| Phase 3 | NCT03462251 | May 2018 → Nov 2021 | hormone receptor-positive breast cancer | iOMEDICO AG | Completed | No outcome recorded |
| Phase 3 | NCT04263298 | May 2018 → May 2025 overdue | breast cancer | Herui Yao | Recruiting | No outcome recorded |
| Phase 3 | NCT03439046 | Feb 2018 → Dec 2023 | breast cancer | Novartis Pharmaceuticals | Terminated | No outcome recorded |
| Phase 3 | NCT03079011 | Mar 2017 → Apr 2021 | breast cancer | UNICANCER | Completed | No outcome recorded |
| Phase 3 | NCT02404051 | Dec 2015 → Jan 2018 | hormone receptor-positive breast cancer, secondary malignant neoplasm | Consorzio Oncotech | Unknown | No outcome recorded |
| Phase 3 | NCT02383030 | Nov 2015 → Sep 2017 | breast cancer | Consorzio Oncotech | Unknown | No outcome recorded |
| Phase 3 | NCT02344472 | Sep 2015 → Jan 2025 | breast cancer | University of Ulm | Unknown | No outcome recorded |
| Phase 3 | NCT02137837 | May 2014 → Dec 2019 | breast cancer | SWOG Cancer Research Network | Terminated | No outcome recorded |
| Phase 3 | NCT02028507 | Mar 2014 → Jan 2019 | breast cancer | Spanish Breast Cancer Research Group | Completed | No outcome recorded |
| Phase 3 | NCT01602380 | Oct 2012 → Apr 2016 | hormone receptor-positive breast cancer | AstraZeneca | Completed | No outcome recorded |
| Phase 3 | NCT01300351 | Mar 2011 → Mar 2014 | breast cancer | AstraZeneca | Completed | No outcome recorded |
| Phase 3 | NCT00944918 | Dec 2008 → Jun 2011 | — | AstraZeneca | Completed | No outcome recorded |
| Phase 3 | NCT00545077 | Nov 2007 → Dec 2013 | breast cancer | Spanish Breast Cancer Research Group | Completed | No outcome recorded |
| Phase 3 | NCT00543127 | Nov 2007 → Jul 2016 | breast cancer | Spanish Breast Cancer Research Group | Terminated | No outcome recorded |
| Phase 3 | NCT00390455 | Sep 2006 → Jul 2014 | HER2 positive breast carcinoma, Her2-receptor negative breast cancer, estrogen-receptor positive breast cancer, progesterone-receptor positive breast cancer | National Cancer Institute (NCI) | Completed | No outcome recorded |
| Phase 3 | NCT00327769 | Nov 2005 → Sep 2007 | female breast carcinoma | AstraZeneca | Completed | No outcome recorded |
| Phase 3 | NCT00099437 | Feb 2005 → Feb 2009 overdue | breast cancer | AstraZeneca | Active not recruiting | No outcome recorded |
| Phase 3 | NCT00075764 | Apr 2004 → Dec 2012 | breast cancer | SWOG Cancer Research Network | Completed | No outcome recorded |
| Phase 3 | NCT00256698 | Jan 2004 → Apr 2009 | breast cancer | AstraZeneca | Completed | No outcome recorded |
| Phase 3 | NCT00065325 | Aug 2003 → Jun 2006 | breast cancer | AstraZeneca | Completed | No outcome recorded |
| Phase 3 | NCT00010153 | Nov 2000 → Oct 2001 | breast cancer | European Organisation for Research and Treatment of Cancer - EORTC | Terminated | No outcome recorded |
| Phase 3 | NCT00241449 | Nov 1998 → Mar 2007 | breast cancer, metastatic neoplasm | AstraZeneca | Completed | No outcome recorded |
| Phase 3 | NCT00635713 | May 1997 → Sep 2004 | female breast carcinoma | AstraZeneca | Completed | No outcome recorded |
| Phase 47 trials | ||||||
| Phase 4 | NCT05631795 | Aug 2022 → Jun 2025 | breast cancer | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 4 | NCT05362760 | Apr 2022 → Apr 2029 expected | hormone receptor-positive breast cancer | University of Ulm | Recruiting | No outcome recorded |
| Phase 4 | NCT05191914 | Feb → Jul 2022 | breast cancer | Liaoning Cancer Hospital & Institute | Unknown | No outcome recorded |
| Phase 4 | NCT04031885 | Aug 2019 → Aug 2020 | breast cancer | Eli Lilly and Company | Terminated | No outcome recorded |
| Phase 4 | NCT03591549 | Aug 2018 → Aug 2021 | breast cancer | Assiut University | Unknown | No outcome recorded |
| Phase 4 | NCT03355157 | Mar 2018 → Aug 2024 | breast cancer | GBG Forschungs GmbH | Completed | No outcome recorded |
| Phase 4 | NCT02447328 | May 2015 → May 2016 | breast cancer | AstraZeneca | Completed | No outcome recorded |
| Phase not applicable4 trials | ||||||
| — | NCT06856200 | Feb → Oct 2025 overdue | Her2-receptor negative breast cancer, hormone-resistant breast carcinoma | Fudan University | Recruiting | No outcome recorded |
| — | NCT05295043 | Dec 2022 → Jan 2024 | Her2-receptor negative breast cancer | Tianjin Medical University Cancer Institute and Hospital | Unknown | No outcome recorded |
| — | NCT05047848 | Aug 2021 → Jun 2022 | female breast carcinoma | Liaoning Cancer Hospital & Institute | Unknown | No outcome recorded |
| — | NCT00126464 | Nov 2004 → ? | breast cancer | Cedars-Sinai Medical Center | Unknown | No outcome recorded |
Also used as a comparator or background therapy in 211 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT02913430 Comparator | Apr 2018 → Apr 2022 | breast cancer | Shannon Puhalla | Completed | No outcome recorded |
| Phase 139 trials | ||||||
| Phase 1 | NCT07358377 Background | May 2026 → Apr 2027 expected | breast cancer | Atridia Pty Ltd. | Recruiting | No outcome recorded |
| Phase 1 | NCT07480681 Background | Mar 2026 → Mar 2028 expected | — | Shanghai Henlius Biotech | Not yet recruiting | No outcome recorded |
| Phase 1 | NCT07408089 Background | Feb 2026 → Feb 2029 expected | breast cancer | Boundless Bio, Inc. | Recruiting | No outcome recorded |
| Phase 1 | NCT07366632 Comparator | Jan → May 2026 overdue | — | Shanghai Best-Link Bioscience, LLC | Not yet recruiting | No outcome recorded |
| Phase 1 | NCT07318805 Background | Dec 2025 → Apr 2029 expected | colorectal adenocarcinoma, female breast carcinoma, hormone receptor-positive breast cancer, triple-negative breast carcinoma | Pfizer | Recruiting | No outcome recorded |
| Phase 1 | NCT07557004 Background | Sep 2025 → Jun 2027 expected | hormone receptor-positive breast cancer | Nanjing Sanhome Pharmaceutical, Co., Ltd. | Active not recruiting | No outcome recorded |
| Phase 1 | NCT07114601 Background | Aug 2025 → Apr 2030 expected | breast neoplasm, colorectal neoplasm, endometrium neoplasm, gastric neoplasm +3 | Eli Lilly and Company | Recruiting | No outcome recorded |
| Phase 1 | NCT06997029 Background | Aug 2025 → Dec 2028 expected | breast cancer, ovarian cancer | Bristol-Myers Squibb | Recruiting | No outcome recorded |
| Phase 1 | NCT06941142 Background | Apr 2025 → Oct 2027 expected | breast cancer | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | Not yet recruiting | No outcome recorded |
| Phase 1 | NCT07029399 Background | Mar 2025 → Jul 2027 expected | hormone receptor-positive breast cancer, triple-negative breast carcinoma | NiKang Therapeutics, Inc. | Recruiting | No outcome recorded |
| Phase 1 | NCT06756932 Background | Feb 2025 → Jul 2027 expected | hormone receptor-positive breast cancer | BeOne Medicines | Recruiting | No outcome recorded |
| Phase 1 | NCT06625775 Background | Oct 2024 → Nov 2028 expected | HER2 positive breast carcinoma, colorectal cancer, hormone receptor-positive breast cancer, lung carcinoma | TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics) | Recruiting | No outcome recorded |
| Phase 1 | NCT06239467 Background | Feb 2024 → Dec 2026 expected | breast cancer | OnKure, Inc. | Active not recruiting | No outcome recorded |
| Phase 1 | NCT06172322 Background | Dec 2023 → Apr 2025 | hormone receptor-positive breast cancer | Nanjing Chia-tai Tianqing Pharmaceutical | Unknown | No outcome recorded |
| Phase 1 | NCT05870579 Background | Nov 2023 → Dec 2026 expected | breast cancer | Novartis Pharmaceuticals | Active not recruiting | No outcome recorded |
| Phase 1 | NCT05683418 Background | Feb 2023 → Dec 2027 expected | hormone receptor-positive breast cancer | Totus Medicines | Recruiting | No outcome recorded |
| Phase 1 | NCT05384119 Background | Jan 2023 → Apr 2024 | female breast carcinoma | Tvardi Therapeutics, Incorporated | Terminated | No outcome recorded |
| Phase 1 | NCT05307705 Background | May 2022 → Dec 2026 expected | breast cancer | Eli Lilly and Company | Recruiting | No outcome recorded |
| Phase 1 | NCT05216432 Background | Dec 2021 → Apr 2027 expected | Her2-receptor negative breast cancer, PIK3CA-related overgrowth spectrum | Relay Therapeutics, Inc. | Recruiting | No outcome recorded |
| Phase 1 | NCT04856371 Background | Apr 2021 → Mar 2022 | breast cancer | Haihe Biopharma Co., Ltd. | Unknown | No outcome recorded |
| Phase 1 | NCT04498520 Background | Mar 2021 → Jun 2025 | endometrioid adenocarcinoma, fallopian tube carcinoma, female breast carcinoma, hormone receptor-positive breast cancer +4 | Pamela Munster | Withdrawn | No outcome recorded |
| Phase 1 | NCT04726332 Background | Feb 2021 → May 2024 | castration-resistant prostate carcinoma, hormone receptor-positive breast cancer, malignant epithelial tumor of ovary, triple-negative breast carcinoma | Exelixis | Terminated | No outcome recorded |
| Phase 1 | NCT04572295 Background | Oct 2020 → Jun 2026 | breast neoplasm | Eisai Inc. | Completed | No outcome recorded |
| Phase 1 | NCT03939897 Background | Jun 2020 → Jun 2023 overdue | female breast carcinoma, hormone receptor-positive breast cancer | National Cancer Institute (NCI) | Active not recruiting | No outcome recorded |
| Phase 1 | NCT04247126 Background | Jan 2020 → Jan 2023 | breast cancer, malignant pancreatic neoplasm, small cell lung carcinoma | Syros Pharmaceuticals | Completed | No outcome recorded |
| Phase 1 | NCT04060862 Background | Nov 2019 → Aug 2023 | breast cancer | Hoffmann-La Roche | Terminated | No outcome recorded |
| Phase 1 | NCT03324061 Comparator | Nov 2017 → Jul 2018 | — | Eagle Pharmaceuticals, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT03236974 Comparator | Oct 2017 → Feb 2019 | estrogen-receptor positive breast cancer | AstraZeneca | Completed | No outcome recorded |
| Phase 1 | NCT03134638 Background | May 2017 → May 2020 | breast cancer, ovarian cancer | Syros Pharmaceuticals | Terminated | No outcome recorded |
| Phase 1 | NCT02792465 Background | Nov 2016 → Jun 2025 | breast cancer | University Health Network, Toronto | Completed | No outcome recorded |
| Phase 1 | NCT02599714 Background | Dec 2015 → Mar 2018 | breast cancer | AstraZeneca | Completed | No outcome recorded |
| Phase 1 | NCT02392611 Background | Mar 2015 → Oct 2017 | lymphoma | Gilead Sciences | Completed | No outcome recorded |
| Phase 1 | NCT02219789 Background | Dec 2014 → Mar 2016 | estrogen-receptor positive breast cancer, female breast carcinoma, progesterone-receptor positive breast cancer | Mayo Clinic | Completed | No outcome recorded |
| Phase 1 | NCT02260661 Background | Nov 2014 → Jul 2016 | estrogen-receptor positive breast cancer, high grade malignant neoplasm | AstraZeneca | Completed | No outcome recorded |
| Phase 1 | NCT01655225 Background | Jul 2012 → Apr 2019 | breast cancer, cancer of unknown primary site, malignant mesothelioma, metastatic malignant neoplasm +2 | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 1 | NCT01597388 Background | May 2012 → Aug 2016 | breast cancer | AstraZeneca | Completed | No outcome recorded |
| Phase 1 | NCT01597193 Background | Apr 2012 → Dec 2015 | female breast carcinoma | Pfizer | Completed | No outcome recorded |
| Phase 1 | NCT01339442 Background | Nov 2011 → Dec 2016 | estrogen-receptor positive breast cancer, female breast carcinoma | Washington University School of Medicine | Completed | No outcome recorded |
| Phase 1 | NCT01296555 Background | Mar 2011 → Jun 2021 | non-Hodgkin lymphoma | Genentech, Inc. | Terminated | No outcome recorded |
| Phase 1/223 trials | ||||||
| Phase 1/2 | NCT07558733 Background | Apr 2026 → May 2029 expected | hormone receptor-positive breast cancer | Faeth Therapeutics | Recruiting | No outcome recorded |
| Phase 1/2 | NCT07287917 Background | Jan 2026 → Feb 2028 expected | cutaneous melanoma, hormone receptor-positive breast cancer | Aminex Therapeutics, Inc. | Recruiting | No outcome recorded |
| Phase 1/2 | NCT07109726 Background | Sep 2025 → Dec 2028 expected | breast cancer, cervical cancer, endometrial cancer, esophageal squamous cell carcinoma +3 | Terremoto Biosciences Inc. | Recruiting | No outcome recorded |
| Phase 1/2 | NCT07708194 Background | Jun 2025 → Feb 2027 expected | HER2 positive breast carcinoma, hormone receptor-positive breast cancer | Tianjin Medical University Cancer Institute and Hospital | Recruiting | No outcome recorded |
| Phase 1/2 | NCT06993844 Background | Jun 2025 → Jun 2027 expected | breast cancer | Ensem Therapeutics | Recruiting | No outcome recorded |
| Phase 1/2 | NCT06736704 Background | Feb 2025 → Apr 2027 expected | cancer | Pikavation Therapeutics, Inc. | Recruiting | No outcome recorded |
| Phase 1/2 | NCT06431243 Background | May 2024 → May 2026 overdue | neoplasm | Chengdu Zenitar Biomedical Technology Co., Ltd | Recruiting | No outcome recorded |
| Phase 1/2 | NCT05985655 Background | Jul 2023 → Jan 2028 expected | head and neck squamous cell carcinoma, hormone receptor-positive breast cancer, non-small cell lung carcinoma, pancreatic adenocarcinoma +2 | Exscientia AI Limited | Recruiting | No outcome recorded |
| Phase 1/2 | NCT05768139 Background | Apr 2023 → Jul 2030 expected | breast cancer | Eli Lilly and Company | Recruiting | No outcome recorded |
| Phase 1/2 | NCT05735080 Background | Mar 2023 → Jul 2027 expected | hormone receptor-positive breast cancer, metastatic malignant neoplasm, ovarian cancer | Incyclix Bio | Recruiting | No outcome recorded |
| Phase 1/2 | NCT05573126 Background | Jan 2023 → Feb 2028 expected | hormone receptor-positive breast cancer | Ellipses Pharma | Recruiting | No outcome recorded |
| Phase 1/2 | NCT05230810 Background | Aug 2022 → Mar 2026 overdue | HER2 positive breast carcinoma | Criterium, Inc. | Active not recruiting | No outcome recorded |
| Phase 1/2 | NCT04923542 Background | Nov 2021 → Nov 2026 expected | hormone receptor-positive breast cancer, metastatic malignant neoplasm in the brain | H. Lee Moffitt Cancer Center and Research Institute | Recruiting | No outcome recorded |
| Phase 1/2 | NCT05054374 Background | Sep 2021 → Oct 2023 | Her2-receptor negative breast cancer | Memorial Sloan Kettering Cancer Center | Completed | No outcome recorded |
| Phase 1/2 | NCT04355520 Background | Jul 2020 → Jun 2021 | hormone receptor-positive breast cancer | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Unknown | No outcome recorded |
| Phase 1/2 | NCT04115306 Background | Nov 2019 → Dec 2026 expected | secondary malignant neoplasm | Phoenix Molecular Designs | Active not recruiting | No outcome recorded |
| Phase 1/2 | NCT04539496 Background | May 2018 → Jul 2023 overdue | breast cancer, metastatic neoplasm | Sihuan Pharmaceutical Holdings Group Ltd. | Active not recruiting | No outcome recorded |
| Phase 1/2 | NCT03363893 Background | Nov 2017 → Dec 2022 | high grade malignant neoplasm | Carrick Therapeutics Limited | Completed | No outcome recorded |
| Phase 1/2 | NCT02983604 Background | Jan 2017 → Jul 2018 | estrogen-receptor positive breast cancer | Gilead Sciences | Terminated | No outcome recorded |
| Phase 1/2 | NCT02983071 Background | Jan 2017 → Jun 2023 | breast carcinoma | G1 Therapeutics, Inc. | Unknown | No outcome recorded |
| Phase 1/2 | NCT01992952 Background | May 2014 → Mar 2019 overdue | estrogen-receptor positive breast cancer | Velindre NHS Trust | Active not recruiting | No outcome recorded |
| Phase 1/2 | NCT01202591 Background | Dec 2010 → Sep 2014 | estrogen-receptor positive breast cancer | AstraZeneca | Completed | No outcome recorded |
| Phase 1/2 | NCT00903006 Comparator | Nov 2009 → May 2013 | breast cancer | M.D. Anderson Cancer Center | Terminated | No outcome recorded |
| Phase 289 trials | ||||||
| Phase 2 | NCT07679269 Background | Jan 2027 → Jun 2031 expected | PIK3CA-related overgrowth spectrum, breast neoplasm | Novartis Pharmaceuticals | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07619066 Background | Oct 2026 → Sep 2028 expected | female breast carcinoma, hormone receptor-positive breast cancer | MedSIR | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07666555 Background | Jun 2026 → Jun 2028 expected | breast cancer | Fudan University | Recruiting | No outcome recorded |
| Phase 2 | NCT07610720 Background | Jun 2026 → Nov 2028 expected | HER2 positive breast carcinoma | Sun Yat-sen University | Recruiting | No outcome recorded |
| Phase 2 | NCT07618390 Background | Jun 2026 → Dec 2028 expected | breast cancer | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07405801 Background | Apr 2026 → Dec 2028 expected | breast cancer | Hoffmann-La Roche | Recruiting | No outcome recorded |
| Phase 2 | NCT07426822 Background | Apr 2026 → Apr 2027 expected | hormone receptor-positive breast cancer | Maryam Lustberg | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07368998 Background | Feb 2026 → Oct 2028 expected | breast cancer | Hoffmann-La Roche | Recruiting | No outcome recorded |
| Phase 2 | NCT06849947 Comparator | Feb 2026 → Jun 2031 expected | breast carcinoma | Yeon Hee Park | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07180160 Background | Sep 2025 → Sep 2027 expected | female breast carcinoma | Wenjin Yin | Recruiting | No outcome recorded |
| Phase 2 | NCT07117630 Background | Sep 2025 → Jun 2027 expected | breast cancer | Fudan University | Recruiting | No outcome recorded |
| Phase 2 | NCT06486883 Comparator | Jun 2025 → Jan 2027 expected | hormone receptor-positive breast cancer | MedSIR | Recruiting | No outcome recorded |
| Phase 2 | NCT06702618 Background | Feb 2025 → Jun 2026 overdue | breast cancer | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Active not recruiting | No outcome recorded |
| Phase 2 | NCT02958852 Background | Jan 2025 | breast cancer | Lund University Hospital | Completed | No outcome recorded |
| Phase 2 | NCT06369285 Background | Nov 2024 → Jun 2027 expected | hormone receptor-positive breast cancer | Puma Biotechnology, Inc. | Recruiting | No outcome recorded |
| Phase 2 | NCT06561022 Background | Aug 2024 → Dec 2025 overdue | breast cancer | Fudan University | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT06179303 Background | Jul 2024 → Mar 2027 expected | female breast carcinoma, hormone receptor-positive breast cancer | University of Washington | Recruiting | No outcome recorded |
| Phase 2 | NCT06339281 Comparator | May 2024 → Jun 2026 overdue | breast cancer | Li Huiping | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT06176534 Comparator | Jan 2024 → Dec 2025 overdue | Her2-receptor negative breast cancer, female breast carcinoma | Henan Cancer Hospital | Recruiting | No outcome recorded |
| Phase 2 | NCT06341894 Background | Nov 2023 → Jun 2027 expected | female breast carcinoma | The First Affiliated Hospital with Nanjing Medical University | Recruiting | No outcome recorded |
| Phase 2 | NCT05625087 Background | Oct 2023 → Jul 2028 expected | breast cancer | UNICANCER | Active not recruiting | No outcome recorded |
| Phase 2 | NCT05872347 Background | Sep 2023 → Dec 2026 expected | metastatic malignant neoplasm in the brain | Shanghai Pharmaceuticals Holding Co., Ltd | Recruiting | No outcome recorded |
| Phase 2 | NCT05949541 Background | Jul 2023 → Jul 2026 overdue | breast cancer | Fudan University | Recruiting | No outcome recorded |
| Phase 2 | NCT05983107 Background | Jul 2023 → Jul 2026 overdue | hormone receptor-positive breast cancer | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Recruiting | No outcome recorded |
| Phase 2 | NCT05966584 Background | Jul 2023 → Aug 2024 | breast cancer | Memorial Sloan Kettering Cancer Center | Terminated | No outcome recorded |
| Phase 2 | NCT04901299 Background | Jul 2023 → Jul 2024 | Her2-receptor negative breast cancer, estrogen-receptor positive breast cancer, invasive breast carcinoma, progesterone-receptor positive breast cancer | Massachusetts General Hospital | Withdrawn | No outcome recorded |
| Phase 2 | NCT05759546 Background | Feb 2023 → Nov 2025 overdue | breast carcinoma | Fudan University | Recruiting | No outcome recorded |
| Phase 2 | NCT05759572 Background | Feb 2023 → Nov 2025 overdue | breast carcinoma | Fudan University | Recruiting | No outcome recorded |
| Phase 2 | NCT05720260 Background | Jan 2023 → Dec 2024 overdue | estrogen-receptor positive breast cancer | National Taiwan University Hospital | Recruiting | No outcome recorded |
| Phase 2 | NCT05594095 Background | Dec 2022 → Dec 2025 overdue | female breast carcinoma, hormone receptor-positive breast cancer | Fudan University | Recruiting | No outcome recorded |
| Phase 2 | NCT04920708 Background | Dec 2022 → Jun 2027 expected | estrogen-receptor positive breast cancer | Royal Marsden NHS Foundation Trust | Active not recruiting | No outcome recorded |
| Phase 2 | NCT05463601 Background | Aug 2022 → Jan 2025 overdue | breast cancer | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | Active not recruiting | No outcome recorded |
| Phase 2 | NCT05472792 Comparator | May 2022 → Apr 2027 expected | breast cancer | UNC Lineberger Comprehensive Cancer Center | Recruiting | No outcome recorded |
| Phase 2 | NCT04899349 Background | Apr 2022 → May 2023 | breast cancer | Novartis Pharmaceuticals | Terminated | No outcome recorded |
| Phase 2 | NCT05181033 Comparator | Dec 2021 → Aug 2027 expected | breast cancer | National University Hospital, Singapore | Recruiting | No outcome recorded |
| Phase 2 | NCT05085002 Background | Dec 2021 → Nov 2023 | female breast carcinoma | EQRx, Inc. | Terminated | No outcome recorded |
| Phase 2 | NCT05041842 Background | Dec 2021 → Apr 2025 overdue | metastatic malignant neoplasm in the brain | UNICANCER | Active not recruiting | No outcome recorded |
| Phase 2 | NCT05090358 Background | Oct 2021 → Oct 2026 expected | breast cancer | Memorial Sloan Kettering Cancer Center | Active not recruiting | No outcome recorded |
| Phase 2 | NCT04762979 Background | Feb 2021 → Oct 2025 overdue | hormone receptor-positive breast cancer | Marina N Sharifi | Active not recruiting | No outcome recorded |
| Phase 2 | NCT04544189 Background | Jan 2021 → Jan 2027 expected | breast neoplasm | Novartis Pharmaceuticals | Active not recruiting | No outcome recorded |
| Phase 2 | NCT04524000 Background | Jan 2021 → Feb 2027 expected | breast cancer | Novartis Pharmaceuticals | Active not recruiting | No outcome recorded |
| Phase 2 | NCT04576455 Comparator | Nov 2020 → Feb 2022 overdue | estrogen-receptor positive breast cancer | Hoffmann-La Roche | Active not recruiting | No outcome recorded |
| Phase 2 | NCT04300790 Background | Oct 2020 → Jun 2022 | breast cancer | MedSIR | Completed | No outcome recorded |
| Phase 2 | NCT04557449 Background | Sep 2020 → Sep 2026 expected | breast neoplasm, liposarcoma, lung adenocarcinoma, prostate cancer | Pfizer | Active not recruiting | No outcome recorded |
| Phase 2 | NCT04352777 Comparator | Sep 2020 → Jun 2025 | hormone receptor-positive breast cancer | Duke University | Completed | No outcome recorded |
| Phase 2 | NCT04460430 Background | Jul 2020 → Nov 2021 | breast cancer | SOLTI Breast Cancer Research Group | Terminated | No outcome recorded |
| Phase 2 | NCT05004142 Background | Jun 2020 → Dec 2021 | breast cancer | Ahon Pharmaceutical Co., Ltd. | Unknown | No outcome recorded |
| Phase 2 | NCT04214288 Comparator | Apr 2020 → Aug 2022 overdue | estrogen-receptor positive breast cancer | AstraZeneca | Active not recruiting | No outcome recorded |
| Phase 2 | NCT04059484 Comparator | Oct 2019 → Feb 2022 | breast cancer | Sanofi | Terminated | No outcome recorded |
| Phase 2 | NCT03781063 Comparator | Sep 2019 → May 2025 | breast cancer | Sermonix Pharmaceuticals Inc. | Completed | No outcome recorded |
| Phase 2 | NCT03620643 Comparator | May 2019 → Aug 2024 | breast lobular carcinoma, gastric cancer, triple-negative breast carcinoma | Royal Marsden NHS Foundation Trust | Completed | No outcome recorded |
| Phase 2 | NCT03809988 Background | Apr 2019 → Nov 2022 | hormone receptor-positive breast cancer | MedSIR | Completed | No outcome recorded |
| Phase 2 | NCT03377101 Background | Aug 2018 | Her2-receptor negative breast cancer, estrogen-receptor positive breast cancer, progesterone-receptor positive breast cancer | National Cancer Institute (NCI) | Withdrawn | No outcome recorded |
| Phase 2 | NCT03555877 Background | Mar 2018 → Jul 2022 | breast carcinoma | GBG Forschungs GmbH | Completed | No outcome recorded |
| Phase 2 | NCT03321981 Background | Jan 2018 → Oct 2022 | breast carcinoma | Merus B.V. | Completed | No outcome recorded |
| Phase 2 | NCT03241810 Background | Aug 2017 → Nov 2018 | breast cancer | Elevation Oncology | Terminated | No outcome recorded |
| Phase 2 | NCT03227328 Comparator | Aug 2017 → Feb 2022 | hormone receptor-positive breast cancer | Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS | Completed | No outcome recorded |
| Phase 2 | NCT02953860 Background | Jul 2017 → Nov 2019 | breast cancer | University of Colorado, Denver | Completed | No outcome recorded |
| Phase 2 | NCT03184090 Background | Jun 2017 → Oct 2020 | metastatic malignant neoplasm | MedSIR | Completed | No outcome recorded |
| Phase 2 | NCT03007979 Background | Jun 2017 → Mar 2020 | breast carcinoma | Washington University School of Medicine | Completed | No outcome recorded |
| Phase 2 | NCT03024580 Comparator | Mar 2017 → Mar 2020 | breast neoplasm | Brazilian National Cancer Institute | Unknown | No outcome recorded |
| Phase 2 | NCT02970682 Background | Oct 2016 → Jan 2019 | breast neoplasm | Evgen Pharma | Completed | No outcome recorded |
| Phase 2 | NCT02630693 Comparator | Apr 2016 → Aug 2018 | breast cancer | Canadian Cancer Trials Group | Completed | No outcome recorded |
| Phase 2 | NCT02632045 Background | Mar 2016 → Jan 2022 | breast carcinoma | Melissa K Accordino | Completed | No outcome recorded |
| Phase 2 | NCT02569801 Comparator | Dec 2015 → Feb 2020 | breast cancer | Genentech, Inc. | Terminated | No outcome recorded |
| Phase 2 | NCT02384239 Background | Oct 2015 → Jan 2021 | hormone receptor-positive breast cancer | University of California, San Francisco | Completed | No outcome recorded |
| Phase 2 | NCT02206984 Comparator | Sep 2015 → Jul 2024 | breast cancer | Priscilla McAuliffe | Completed | No outcome recorded |
| Phase 2 | NCT02530411 Background | Apr 2015 → Dec 2018 | neoplasm | Velindre NHS Trust | Unknown | No outcome recorded |
| Phase 2 | NCT02374099 Background | Mar 2015 → Dec 2016 | breast cancer | Celgene Corporation | Terminated | No outcome recorded |
| Phase 2 | NCT02366130 Background | Feb 2015 → Dec 2020 | breast cancer | M.D. Anderson Cancer Center | Completed | No outcome recorded |
| Phase 2 | NCT02291913 Background | Dec 2014 → Jan 2019 | breast cancer | SCRI Development Innovations, LLC | Completed | No outcome recorded |
| Phase 2 | NCT02269670 Background | Nov 2014 → Jan 2021 | Her2-receptor negative breast cancer, estrogen-receptor positive breast cancer, female breast carcinoma, progesterone-receptor positive breast cancer | Emory University | Terminated | No outcome recorded |
| Phase 2 | NCT02115594 Background | Apr 2014 → Dec 2015 | breast cancer | Syndax Pharmaceuticals | Withdrawn | No outcome recorded |
| Phase 2 | NCT02072512 Comparator | Jan 2014 → Nov 2015 | breast cancer | Hospital Affiliated to Military Medical Science, Beijing | Unknown | No outcome recorded |
| Phase 2 | NCT01797120 Comparator | May 2013 → Mar 2017 | breast cancer | PrECOG, LLC. | Completed | No outcome recorded |
| Phase 2 | NCT01560416 Comparator | Jun 2012 → Jun 2016 | breast cancer | Dana-Farber Cancer Institute | Completed | No outcome recorded |
| Phase 2 | NCT01528345 Background | Apr 2012 → Apr 2015 | breast cancer | Novartis Pharmaceuticals | Terminated | No outcome recorded |
| Phase 2 | NCT01437566 Background | Oct 2011 → Apr 2016 | breast cancer | Genentech, Inc. | Completed | No outcome recorded |
| Phase 2 | NCT01160718 Comparator | Aug 2010 → Dec 2012 | female breast carcinoma | Swiss Cancer Institute | Completed | No outcome recorded |
| Phase 2 | NCT00811369 Background | Aug 2009 → Oct 2012 | breast cancer | Ontario Clinical Oncology Group (OCOG) | Completed | No outcome recorded |
| Phase 2 | NCT00728949 Comparator | Aug 2008 → Mar 2012 | breast cancer | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 2 | NCT00570323 Comparator | Dec 2007 → Oct 2016 | breast cancer | Mothaffar Rimawi | Completed | No outcome recorded |
| Phase 2 | NCT00451555 Background | Apr 2007 → Dec 2010 | breast cancer | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 2 | NCT00454805 Background | Mar 2007 → Dec 2008 | breast cancer | AstraZeneca | Completed | No outcome recorded |
| Phase 2 | NCT00372996 Background | Feb 2007 → Sep 2012 | breast cancer | Pfizer | Terminated | No outcome recorded |
| Phase 2 | NCT00570258 Comparator | Sep 2006 → Dec 2010 | breast cancer | University of Arkansas | Terminated | No outcome recorded |
| Phase 2 | NCT00183963 Comparator | Aug 2006 → Jun 2008 | breast carcinoma | University of Southern California | Terminated | No outcome recorded |
| Phase 2 | NCT00082810 Background | Mar 2004 → Jul 2008 | estrogen-receptor positive breast cancer, female breast carcinoma | National Cancer Institute (NCI) | Completed | No outcome recorded |
| Phase 2 | NCT00206414 Background | Jan 2003 → Sep 2006 | breast cancer | Baylor Breast Care Center | Terminated | No outcome recorded |
| Phase 2/32 trials | ||||||
| Phase 2/3 | NCT05860465 Background | Sep 2023 → Dec 2026 expected | breast cancer | Shanghai Pharmaceuticals Holding Co., Ltd | Recruiting | No outcome recorded |
| Phase 2/3 | NCT04191499 Background | Jan 2020 → Sep 2023 overdue | breast cancer | Hoffmann-La Roche | Active not recruiting | No outcome recorded |
| Phase 353 trials | ||||||
| Phase 3 | NCT07354022 Comparator | May 2026 → Dec 2028 expected | breast cancer | Shandong Suncadia Medicine Co., Ltd. | Recruiting | No outcome recorded |
| Phase 3 | NCT07393321 Background | Feb 2026 → Aug 2028 expected | Her2-receptor negative breast cancer | Nanjing Chia-tai Tianqing Pharmaceutical | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT06585969 Comparator | Jan 2026 | basal-like breast carcinoma, estrogen-receptor positive breast cancer, luminal B breast carcinoma | Danish Breast Cancer Cooperative Group | Withdrawn | No outcome recorded |
| Phase 3 | NCT07174336 Background | Dec 2025 → May 2029 expected | breast cancer, metastatic neoplasm | Eli Lilly and Company | Recruiting | No outcome recorded |
| Phase 3 | NCT07207070 Background | Nov 2025 → May 2029 expected | breast cancer | Risen (Suzhou) Pharma Tech Co., Ltd. | Recruiting | No outcome recorded |
| Phase 3 | NCT06982521 Background | Aug 2025 → Apr 2028 expected | hormone receptor-positive breast cancer | Relay Therapeutics, Inc. | Recruiting | No outcome recorded |
| Phase 3 | NCT07024173 Comparator | Jul 2025 → Dec 2026 expected | female breast carcinoma | Shandong Suncadia Medicine Co., Ltd. | Recruiting | No outcome recorded |
| Phase 3 | NCT06929325 Background | Apr 2025 → Oct 2026 expected | hormone receptor-positive breast cancer | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT06680921 Comparator | Nov 2024 → Aug 2028 expected | breast cancer | Jiangsu Simcere Pharmaceutical Co., Ltd. | Recruiting | No outcome recorded |
| Phase 3 | NCT06612814 Background | Sep 2024 → Oct 2027 expected | breast carcinoma | Zhimin Shao | Active not recruiting | No outcome recorded |
| Phase 3 | NCT06380751 Comparator | Aug 2024 → Mar 2029 expected | female breast carcinoma | AstraZeneca | Recruiting | No outcome recorded |
| Phase 3 | NCT06044623 Background | Apr 2024 → Oct 2028 expected | breast cancer | Region Örebro County | Recruiting | No outcome recorded |
| Phase 3 | NCT06447623 Background | Feb 2024 → Feb 2027 expected | hormone receptor-positive breast cancer | Fudan University | Recruiting | No outcome recorded |
| Phase 3 | NCT06065748 Comparator | Dec 2023 → Feb 2027 expected | estrogen-receptor positive breast cancer | Hoffmann-La Roche | Recruiting | No outcome recorded |
| Phase 3 | NCT06016738 Comparator | Nov 2023 → Jun 2026 overdue | Her2-receptor negative breast cancer, estrogen-receptor positive breast cancer | Olema Pharmaceuticals, Inc. | Recruiting | No outcome recorded |
| Phase 3 | NCT05696626 Comparator | Oct 2023 → Apr 2027 expected | breast cancer | LeonaBio | Recruiting | No outcome recorded |
| Phase 3 | NCT05894239 Background | Sep 2023 → Dec 2026 expected | breast cancer | Hoffmann-La Roche | Recruiting | No outcome recorded |
| Phase 3 | NCT05861830 Background | May 2023 → Dec 2025 | female breast carcinoma | Peking Union Medical College Hospital | Unknown | No outcome recorded |
| Phase 3 | NCT05654623 Comparator | Mar 2023 → Jan 2025 overdue | breast cancer | Pfizer | Active not recruiting | No outcome recorded |
| Phase 3 | NCT06954961 Comparator | Sep 2022 → Nov 2026 expected | breast cancer | InventisBio Co., Ltd | Recruiting | No outcome recorded |
| Phase 3 | NCT05306340 Comparator | Aug 2022 → Jul 2025 overdue | estrogen-receptor positive breast cancer | Genentech, Inc. | Active not recruiting | No outcome recorded |
| Phase 3 | NCT05365178 Background | Jul 2022 → Jul 2025 overdue | hormone receptor-positive breast cancer | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Active not recruiting | No outcome recorded |
| Phase 3 | NCT06998108 Comparator | Jun 2022 → Dec 2025 overdue | hormone receptor-positive breast cancer | BeBetter Med Inc | Recruiting | No outcome recorded |
| Phase 3 | NCT05433480 Background | May 2022 → Dec 2023 | breast cancer | Betta Pharmaceuticals Co., Ltd. | Unknown | No outcome recorded |
| Phase 3 | NCT05065411 Comparator | Apr 2022 → Oct 2023 | breast cancer | Veru Inc. | Terminated | No outcome recorded |
| Phase 3 | NCT05207709 Background | Mar 2022 → Mar 2026 | breast cancer | SOLTI Breast Cancer Research Group | Terminated | No outcome recorded |
| Phase 3 | NCT05375461 Background | Mar 2022 → Jan 2024 | hormone receptor-positive breast cancer | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Completed | No outcome recorded |
| Phase 3 | NCT05169567 Background | Mar 2022 → Feb 2024 overdue | breast neoplasm, metastatic neoplasm | Eli Lilly and Company | Active not recruiting | No outcome recorded |
| Phase 3 | NCT05670054 Comparator | Mar 2022 → Oct 2023 | female breast carcinoma | Mansoura University | Unknown | No outcome recorded |
| Phase 3 | NCT05438810 Background | Jan 2022 → Feb 2024 | female breast carcinoma | Ahon Pharmaceutical Co., Ltd. | Unknown | No outcome recorded |
| Phase 3 | NCT05038735 Background | Dec 2021 → Jan 2027 expected | female breast carcinoma | Novartis Pharmaceuticals | Active not recruiting | No outcome recorded |
| Phase 3 | NCT05077449 Background | Nov 2021 → Feb 2024 overdue | breast cancer | Xuanzhu Biopharmaceutical Co., Ltd. | Active not recruiting | No outcome recorded |
| Phase 3 | NCT05054751 Background | Sep 2021 → Dec 2022 | breast cancer | Genor Biopharma Co., Ltd. | Completed | No outcome recorded |
| Phase 3 | NCT04650581 Background | Jan 2021 → May 2025 overdue | breast cancer | Canadian Cancer Trials Group | Active not recruiting | No outcome recorded |
| Phase 3 | NCT04305496 Background | Apr 2020 → May 2023 overdue | breast cancer | AstraZeneca | Active not recruiting | No outcome recorded |
| Phase 3 | NCT03820830 Background | Aug 2019 → Jul 2026 overdue | breast cancer | ETOP IBCSG Partners Foundation | Active not recruiting | No outcome recorded |
| Phase 3 | NCT03927456 Background | Jun 2019 → Dec 2021 | breast cancer | Jiangsu HengRui Medicine Co., Ltd. | Unknown | No outcome recorded |
| Phase 3 | NCT03778931 Comparator | May 2019 → Aug 2021 | breast cancer | Stemline Therapeutics, Inc. | Completed | No outcome recorded |
| Phase 3 | NCT03447132 Comparator | Dec 2017 → Apr 2021 | breast cancer | International Cancer Research Group, United Arab Emirates | Completed | No outcome recorded |
| Phase 3 | NCT03425838 Comparator | Nov 2017 → Mar 2023 overdue | breast cancer | Dutch Breast Cancer Research Group | Active not recruiting | No outcome recorded |
| Phase 3 | NCT02947685 Background | Jun 2017 → Oct 2024 overdue | HER2 positive breast carcinoma, estrogen-receptor positive breast cancer | Alliance Foundation Trials, LLC. | Active not recruiting | No outcome recorded |
| Phase 3 | NCT02763566 Background | Dec 2016 → Mar 2019 overdue | breast cancer | Eli Lilly and Company | Active not recruiting | No outcome recorded |
| Phase 3 | NCT02437318 Background | Jul 2015 → Jun 2018 | breast cancer | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 3 | NCT02422615 Background | Jun 2015 → Nov 2017 | breast cancer | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 3 | NCT02340221 Background | Apr 2015 → Jun 2021 | breast cancer | Hoffmann-La Roche | Terminated | No outcome recorded |
| Phase 3 | NCT02107703 Background | Jul 2014 → Feb 2017 overdue | breast neoplasm | Eli Lilly and Company | Active not recruiting | No outcome recorded |
| Phase 3 | NCT01953588 Comparator | Feb 2014 → Apr 2027 expected | Her2-receptor negative breast cancer, estrogen-receptor positive breast cancer, female breast carcinoma, invasive ductal breast carcinoma +1 | Alliance for Clinical Trials in Oncology | Active not recruiting | No outcome recorded |
| Phase 3 | NCT01942135 Comparator | Sep 2013 → Dec 2014 | breast cancer | Pfizer | Completed | No outcome recorded |
| Phase 3 | NCT01633060 Background | Oct 2012 → May 2016 | breast cancer | Novartis Pharmaceuticals | Terminated | No outcome recorded |
| Phase 3 | NCT01610284 Background | Aug 2012 → Apr 2015 | breast cancer | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 3 | NCT00688194 Comparator | May 2008 → May 2013 | breast cancer | Gruppo Italiano Mammella (GIM) | Unknown | No outcome recorded |
| Phase 3 | NCT02394496 Background | Nov 2007 → Dec 2016 | breast cancer | Consorzio Oncotech | Unknown | No outcome recorded |
| Phase 3 | NCT00253422 Comparator | Mar 2004 → Nov 2022 | breast cancer | Institute of Cancer Research, United Kingdom | Completed | No outcome recorded |
| Phase 43 trials | ||||||
| Phase 4 | NCT05161195 Background | Jul 2022 → Jun 2030 expected | metastatic malignant neoplasm | Novartis Pharmaceuticals | Active not recruiting | No outcome recorded |
| Phase 4 | NCT04707196 Background | Feb 2021 → Jan 2023 | breast cancer, metastatic malignant neoplasm | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 4 | NCT03220178 Background | Jul 2017 → Dec 2021 | breast cancer | Palleos Healthcare GmbH | Terminated | No outcome recorded |
| Phase not applicable1 trial | ||||||
| — | NCT05890287 Background | May 2023 → May 2026 overdue | hormone receptor-positive breast cancer | Tianjin Medical University Cancer Institute and Hospital | Recruiting | No outcome recorded |
Press releases naming this drug 8 releases
| Date | Issuer | Release |
|---|---|---|
| 2024-06-20 | AstraZeneca | Truqap plus Faslodex approved in the EU for patients with advanced ER-positive breast cancer astrazeneca.com ↗ |
| 2024-04-29 | AstraZeneca | Truqap plus Faslodex recommended for approval in the EU by CHMP for patients with advanced ER-positive breast cancer astrazeneca.com ↗ |
| 2024-03-27 | AstraZeneca | Truqap plus Faslodex approved in Japan for patients with advanced HR-positive breast cancer astrazeneca.com ↗ |
| 2023-11-17 | AstraZeneca | Truqap (capivasertib) plus Faslodex approved in the US for patients with advanced HR-positive breast cancer astrazeneca.com ↗ |
| 2019-12-12 | Novartis Pharmaceuticals | Novartis Kisqali® data show superior overall survival compared to fulvestrant and consistent efficacy across advanced breast cancer patient subgroups in MONALEESA-3 novartis.com ↗ |
| 2018-12-06 | Novartis Pharmaceuticals | Novartis investigational BYL719 (alpelisib) plus fulvestrant consistently improved PFS in patients with PIK3CA mutated HR+/HER2- advanced breast cancer in new SOLAR-1 analyses novartis.com ↗ |
| 2018-10-20 | Novartis Pharmaceuticals | Novartis investigational BYL719 (alpelisib) plus fulvestrant nearly doubles median PFS in patients with PIK3CA mutated HR+/HER2- advanced breast cancer compared to fulvestrant alone novartis.com ↗ |
| 2018-07-18 | Novartis Pharmaceuticals | Novartis Kisqali® now first and only CDK4/6 inhibitor indicated in US as first-line therapy specifically for premenopausal women; and as initial therapy with fulvestrant in postmenopausal women novartis.com ↗ |
Evidence & citations 13 cited values
Every value below carries the sentence it was read from. 513 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Fulvestrant | “Patients will be enrolled into the study and assign to receive Palbociclib 125 mg/day orally for 3 weeks followed by 1 week off plus fulvestrant 500 mg intramuscularly on Days...” NCT04318223 ↗504“Options include tamoxifen (20 mg daily), aromatase inhibitors (letrozole 2.5 mg daily, anastrozole 1 mg daily, or exemestane 25 mg daily), or fulvestrant (500 mg...” NCT07708194 ↗ “Endocrine therapy is determined by the doctor, including any kind of letrozole, anastrozole, exemestane, fulvestrant, tamoxifen, toremifene, combined with or without drugs or...” NCT03204734 ↗ “The study is designed to evaluate the safety, tolerability, and pharmacokinetics (PK) of a single dose of Fulvestrant for Injectable Suspension vs. the reference drug,...” NCT03324061 ↗ “Endocrine therapy (physician's choice based on prior administered agent including tamoxifen, exemestane, fulvestrant, anastrozole, or letrozole). Endocrine therapy must be...” NCT03184090 ↗ “This single-arm, phase Ib trial evaluated the antitumor activities and safety of afuresertib (apan AKT inhibitor) plus fulvestrant for previously treated HR-positive,...” PMID 41651834 ↗ Feb 2026 “Cohort A is for patients with HR+/HER2- (hormone receptor positive/human epidermal growth factor receptor 2 negative) advanced breast cancer treated with PM in combination with...” NCT06431243 ↗ “Patients with HR-positive, HER2-negative, locally recurrent or metastatic breast cancer were randomized (2:1) to receive culmerciclib plus fulvestrant or matching placebo plus...” PMID 41413016 ↗ Dec 2025 “Futibatinib 20mg once daily on a 28-day cycle and fulvestrant 500 mg administered intramuscularly (IM) on Days 1 and 15 of Cycle 1, then on Day 1 of Cycle 2 and beyond on a...” NCT04024436 ↗ “We tested this hypothesis in a phase II neoadjuvant trial of anastrozole and fulvestrant combined with gefitinib in postmenopausal women with newly diagnosed ER-positive breast cancer.” PMID 21792626 ↗ Jul 2011 “Participants will receive selected SoC regimen (fulvestrant, paclitaxel + bevacizumab, pegylated liposomal doxorubicin, or capecitabine) administered as specified in the treatment arm.” NCT05985655 ↗ “Endocrine therapy: letrozole (2.5mg daily), anastrozole (1mg daily), exemestane (25mg daily), tamoxifen (20mg daily) or fulvestrant (intramuscular 500mg every 4 weeks)” NCT06585969 ↗ “Fulvestrant 500 mg versus anastrozole 1 mg for hormone receptor-positive advanced breast cancer (FALCON): an international, randomised, double-blind, phase 3 trial.” PMID 27908454 ↗ Nov 2016 “Fulvestrant: 500 mg administered intramuscularly (IM) into the buttocks as two 5 mL injections on C1D1, C1D15 and C2D1 and Day 1 of every subsequent 28-day cycle” NCT03778931 ↗ “Participants will receive standard of care SERD therapy in the form of Fulvestrant, in combination with one of three one of three available CDK4/6i therapies:” NCT05826964 ↗ “Fulvestrant: 2 intramuscular injections of 500 mg given on Day 1 of Weeks 1 and 3 of cycle 1, and then on Day 1, Week 1 of each cycle thereafter.” NCT04305496 ↗ “Anastrozole (1 mg/day) or letrozole (2.5 mg/day) or fulvestrant (2x250 mg at day 1 and day 15 then every 4 weeks after the first injection)” NCT05041842 ↗ “Fulvestrant: 500 mg, intramuscular injection on day 1/15 of the first cycle, then on day 1 of each subsequent cycle, every 28 days” NCT05861830 ↗ “1. Fulvestrant intramuscular injection of two 250mg injection every 4 weeks (every 2 weeks for the first cycle, 1 cycle = 4 weeks)” NCT06837792 ↗ “The hormone therapy will be either letrozole by mouth once a day at home, or fulvestrant as a shot into the muscle.” NCT03519178 ↗ “Letrozole 2.5mg, Anastrozole 1mg, Exemestane 25mg, or Fulvestrant 0.5g IM on Days 1, 28 (initial: Days 1, 15, 28)” NCT07610720 ↗ “A single hormonal agent (ie, Tamoxifen or Aromatase Inhibitor or Fulvestrant) administered daily while on study.” NCT02366130 ↗ “Tamoxifen, letrozole, anastrozole, exemestane, fulvestrant, etc, selected at the discretion of the investigator.” NCT05983107 ↗ “Palbociclib+ fulvestrant VS Ribociclib + fulvestrant as a second line treatment in metastatic ER+ve her2 -ve BC” NCT05670054 ↗ “Hormone therapy using fulvestrant may fight breast cancer by lowering the amount of estrogen the body makes.” NCT00138125 ↗ “physician's choice of endocrine therapy (ET) including fulvestrant, letrozole, anastrozole, and exemestane” NCT06486883 ↗ “Fulvestrant is a selective estrogen receptor down-regulator that competitively binds to estrogen receptors” NCT03591549 ↗ “500 mg of fulvestrant intramuscular injection on Study Day 1, 15, 29, and once every 28 days thereafter” NCT06369285 ↗ “Non-steroidal AIs (anastrozole, letrozole); steroidal AI (exemestane); Fulvestrant or Tamoxifen” NCT02448420 ↗ “Either Letrozole, Anastrozole, Exemestane or Fulvestrant in combination with CDK 4/6-inhibitor” NCT06044623 ↗ “Milademetan and Fulvestrant in GATA3-mutant, ER+HER- Advanced or Metastatic Breast Cancer” NCT05932667 ↗ “fulvestrant (Faslodex) injection once every 2 weeks for 3 doses then every month” NCT03820830 ↗ “Aromatase inhibitors or fulvestrant administered as approved product label” NCT07683754 ↗ “Fulvestrant, Imlunestrant, Aromatase Inhibitors, Capecitabine, Abemaciclib” NCT07114601 ↗ “Endocrine therapy can consist of fulvestrant or an aromatase inhibitor.” NCT04923542 ↗ “Endocrine therapy: * non-steroidal or steroidal AI * fulvestrant” NCT03227328 ↗ “Chidamide+ exemestane/Fulvestrant/Letrozole/Anastrozole/Tamoxifen” NCT05890287 ↗ “PI3K inhibitor + anti-estrogen therapy ( alpelisib + fulvestrant)” NCT04965688 ↗ “Alpelisib 300 mg once daily + fulvestrant 500 mg every 28 days” NCT05625087 ↗ “plus endocrine therapy (fulvestrant or aromatase inhibitors)” NCT07037199 ↗ “Fulvestrant injection：Administered by intravenous infusion” NCT05860465 ↗ “Fulvestrant injection：Administered by intravenous infusion” NCT05872347 ↗ “Neratinib plus Fulvestrant, Exemestane or Tamoxifen” NCT04460430 ↗ “Endocrine therapy alone (letrozole or fulvestrant)” NCT03809988 ↗ “CDK4/6 inhibitor + AI/fulvestrant therapy” NCT05295043 ↗ “fulvestrant (500 mg intramuscular” NCT03386162 ↗ “fulvestrant 500mg per 28 days” NCT06176534 ↗ “Drug: Fulvestrant” NCT05054374 ↗ “or fulvestrant” NCT05894239 ↗ “Fulvestrant/AI” NCT06341894 ↗ “Fulvestrant” NCT05411380 ↗ “fulvestrant” NCT03321981 ↗ “Fulvestrant” NCT05205200 ↗ “Fulvestrant” NCT04355858 ↗ |
| Known as | Faslodex | “Single-arm study with the primary objective of assessing the efficacy and safety of palbociclib in combination with fulvestrant (Faslodex) in women with HR+, HER2-negative...” NCT04318223 ↗24“The study is designed to evaluate the safety, tolerability, and pharmacokinetics (PK) of a single dose of Fulvestrant for Injectable Suspension vs. the reference drug,...” NCT03324061 ↗ “A Randomized, Open-Label Phase II Clinical Trial of Combination Erlotinib (Tarceva®) and Fulvestrant (Faslodex®) Versus Erlotinib (Tarceva®) Alone in Advanced Non-Small Cell...” NCT00100854 ↗ “Reference Product: Faslodex® (Fulvestrant), 5 mL pre-filled syringe containing 250 mg/5 mL of fulvestrant, administered as two 5 mL injections (total 500 mg) via intramuscular...” NCT06995482 ↗ “The main purpose of this research study is to see if adding fulvestrant (Faslodex) to erlotinib (Tarceva) is effective in patients with stage IIIb/IV Non-Small Cell Lung Cancer.” NCT00592007 ↗ “Combined with a background therapy of 500 mg Fulvestrant (Faslodex®) (once a month intramuscular injection, with an additional 500 mg dose given two weeks after the first dose)” NCT03099174 ↗ “Drug: Fulvestrant Participants will receive intramuscular (IM) fulvestrant every 2 weeks during Cycle 1 and then every 4 weeks Other Names: • Faslodex” NCT06757634 ↗ “A Phase II Trial to Evaluate the Combination of ZD1839 (Iressa) and Fulvestrant (Faslodex®) in Patients With Advanced or Metastatic Breast Cancer” NCT00234403 ↗ “Fulvestrant(which also goes by the tradename, Faslodex) was recently approved by the Food and Drug Administration (FDA) to treat breast cancer.” NCT01186796 ↗ “They are being offered voluntary admission to this study to test the effects of a new investigational drug called Fulvestrant (Faslodex).” NCT00183963 ↗ “Compare the Efficacy and Tolerability of Fulvestrant (FASLODEX) 500 mg With Anastrozole (ARIMIDEX) 1 mg as Hormonal Treatment” NCT01602380 ↗ “Fulvestrant (Faslodex) IM 250 mg monthly after a loading dose of 500 mg on day 1 and 250 mg on day 15 of cycle 1.” NCT00932152 ↗ “fulvestrant (Faslodex) injection once every 2 weeks for 3 doses then every month” NCT03820830 ↗ “together with fulvestrant (an endocrine therapy also called Faslodex)” NCT07227233 ↗ “palbociclib in combination with fulvestrant (Faslodex®)” NCT01942135 ↗ “Fulvestrant(Faslodex® ) as 2nd Line and Later Therapy” NCT02447328 ↗ “500mg Fulvestrant (Faslodex)” NCT03202862 ↗ “ICI 182,780 (Faslodex)” NCT00417430 ↗ “Faslodex” NCT01300351 ↗ |
| Known as | Fulvestrant (Faslodex) | “Fulvestrant (Faslodex)” NCT02000596 ↗ |
| Known as | Fulvestrant mylan | ChEMBL registry synonym — accepted as the source's own label CHEMBL1358 ↗ |
| Known as | ICI 182,780 | “Faslodex (Long Acting ICI 182,780)” NCT00635713 ↗ |
| Known as | KSHN001034 | “Open Label Sequential Dosing Single Ascending Dose of Four Cohort and Multiple Dose of One Cohort Pharmacokinetics Tolerability and Safety of Fulvestrant Injection as Test...” NCT06074757 ↗ |
| Known as | NSC #719276 | “Combination Fulvestrant (NSC #719276) Plus ZD1839” NCT00057941 ↗ |
| Known as | NSC-759879 | ChEMBL registry synonym — accepted as the source's own label CHEMBL1358 ↗ |
| Known as | ZD-9238 | ChEMBL registry synonym — accepted as the source's own label CHEMBL1358 ↗ |
| Action | Inhibit | “Hormone therapy using fulvestrant may fight cancer by blocking the uptake of estrogen by the tumor cells.” NCT00006903 ↗ |
| Modality | Small molecule | “the steroidal anti-oestrogen fulvestrant” PMID 23902874 ↗ Jul 2013 |
| Route | Intramuscular | “Given intramuscularly” NCT00006903 ↗ |
| Target | AR | “fulvestrant downregulates androgen receptor (AR)” NCT00476645 ↗ |